Spruce Biosciences, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Spruce Biosciences, Inc. (SPRB) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-12
- Spruce Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $3.91M.
- Spruce Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$2.05M.
- Spruce Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$841.00K, a 157.45% decline year-over-year.
- Spruce Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$719.00K.
- Spruce Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$2.45M.
- Spruce Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$391.00K, a 114.83% decline from fiscal 2023.
- Spruce Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $2.64M, a 222.64% increase from fiscal 2022.
- Spruce Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $817.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.85M 10-Q · filed 2026-08-12 | $1.01M derived: sum of 3 quarters · filed 2026-08-12 | $293.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$2.05M 10-Q · filed 2026-05-13 | -$2.90M derived: sum of 2 quarters · filed 2026-05-13 | -$3.61M derived: sum of 3 quarters · filed 2026-05-13 | -$4.01M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$841.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$1.56M derived: sum of 2 quarters · filed 2026-03-09 | -$1.96M derived: sum of 3 quarters · filed 2026-08-12 | -$2.45M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$719.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$1.11M derived: sum of 2 quarters · filed 2026-08-12 | -$1.61M 10-Q · filed 2025-11-10 | -$142.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$395.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$887.00K 10-Q · filed 2026-08-12 | $577.00K derived: sum of 3 quarters · filed 2026-08-12 | -$551.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$492.00K 10-Q · filed 2026-05-13 | $972.00K derived: sum of 2 quarters · filed 2026-05-13 | -$156.00K derived: sum of 3 quarters · filed 2026-05-13 | -$1.07M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $336.00K derived: sum of 2 quarters · filed 2026-03-09 | -$582.00K derived: sum of 3 quarters · filed 2026-03-09 | -$391.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$2.05M derived: sum of 2 quarters · filed 2025-11-10 | -$1.85M 10-Q · filed 2025-11-10 | $1.73M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$918.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$727.00K 10-Q · filed 2025-08-14 | $2.85M derived: sum of 3 quarters · filed 2025-08-14 | $2.62M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $191.00K 10-Q · filed 2025-05-06 | $3.77M derived: sum of 2 quarters · filed 2025-05-06 | $3.54M derived: sum of 3 quarters · filed 2025-05-06 | $3.49M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $3.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $3.35M derived: sum of 2 quarters · filed 2025-04-15 | $3.30M derived: sum of 3 quarters · filed 2025-04-15 | $2.64M 10-K · filed 2025-04-15 |
| 2023-09-30 | -$236.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$281.00K derived: sum of 2 quarters · filed 2024-11-12 | -$945.00K 10-Q · filed 2024-11-12 | $12.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$709.00K 10-Q · filed 2024-08-12 | $248.00K derived: sum of 3 quarters · filed 2024-08-12 | -$177.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$664.00K 10-Q · filed 2024-05-13 | $293.00K derived: sum of 2 quarters · filed 2024-05-13 | -$132.00K derived: sum of 3 quarters · filed 2024-05-13 | -$669.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $957.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $532.00K derived: sum of 2 quarters · filed 2024-03-18 | -$5.00K derived: sum of 3 quarters · filed 2024-03-18 | $817.00K 10-K · filed 2024-03-18 |
| 2022-09-30 | -$425.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$962.00K derived: sum of 2 quarters · filed 2023-11-13 | -$140.00K 10-Q · filed 2023-11-13 | $1.18M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$537.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $285.00K 10-Q · filed 2023-08-14 | $1.61M derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $822.00K 10-Q · filed 2023-05-15 | $2.15M derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$415.00K 10-K · filed 2023-03-16 | ||
| 2021-09-30 | -$1.74M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |